Journal
CURRENT DRUG TARGETS
Volume 15, Issue 6, Pages 622-634Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450115666140306152642
Keywords
Combined therapy; hematologic malignancies; histone deacetylase inhibitors; monotherapy; panobinostat; solid tumors
Categories
Funding
- National Scientific and Technological Major Project of Ministry of Science and Technology of China [2011ZX09401-015]
- National Natural Science Foundation of China [21302111, 21172134]
- China Postdoctoral Science Foundation [2013M540558]
- Postdoctoral Innovation Project Foundation of Shandong Province [201303090]
- Independent Innovation Foundation of Shandong University, IIFSDU [2013GN013]
- National Cancer Institute of the National Institute of Health [R01CA163452]
- National High-tech R&D Program of China, 863 Program [2014AA020523]
Ask authors/readers for more resources
Histone deacetylases are a class of enzymes that play important roles in post translational modifications of histones by deacetylating the lysine residues as well as interacting with various non-histone proteins. This type of enzymes is closely related to oncogenesis and has been proved to be attractive targets for designing novel anti-cancer agents. Over the last 10 years, a large number of HDACs have entered pre-clinical and/or clinical trials. Among these drug candidates, the pan-HDAC inhibitor, panobinostat demonstrated high therapeutic potential as monotherapy and combined therapy in both preclinical models and clinical cancer patients. In this review, we have mainly focused on the recent progress of the clinical studies about panobinostat, and discussed its anti-cancer effects and molecular rationale for the treatment strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available